387 related articles for article (PubMed ID: 23707166)
21. Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.
Van Der Meeren O; Crasta P; Cheuvart B; De Ridder M
Hum Vaccin Immunother; 2015; 11(7):1726-9. PubMed ID: 25996260
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease.
Kwon JY; Daoud ND; Hashash JG; Picco MF; Farraye FA
Inflamm Bowel Dis; 2023 Feb; 29(2):254-259. PubMed ID: 35468183
[TBL] [Abstract][Full Text] [Related]
24. A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis.
Manley HJ; Aweh G; Frament J; Ladik V; Lacson EK
Nephrol Dial Transplant; 2023 Feb; 38(2):447-454. PubMed ID: 35150277
[TBL] [Abstract][Full Text] [Related]
25. Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States.
Splawn LM; Bailey CA; Medina JP; Cho JC
Drugs Today (Barc); 2018 Jul; 54(7):399-405. PubMed ID: 30090877
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of an Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) in Patients With Inflammatory Bowel Disease.
Corral JE; Kwon JY; Caldera F; Pungpapong S; Spaulding AC; Borah BJ; Moriarty JP; Farraye FA
Crohns Colitis 360; 2021 Jan; 3(1):otaa090. PubMed ID: 36777070
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
Janssen JM; Heyward WL; Martin JT; Janssen RS
Vaccine; 2015 Feb; 33(7):833-7. PubMed ID: 25576215
[TBL] [Abstract][Full Text] [Related]
28. Primary high-dose intradermal hepatitis B vaccination in hemodialysis: cost-effectiveness evaluation at 2 years.
Mat O; Mestrez F; Beauwens R; Muniz-Martinez MC; Dhaene M
Hemodial Int; 2006 Jan; 10(1):49-55. PubMed ID: 16441827
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
[TBL] [Abstract][Full Text] [Related]
30. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials.
Alavian SM; Tabatabaei SV
Clin Ther; 2010 Jan; 32(1):1-10. PubMed ID: 20171406
[TBL] [Abstract][Full Text] [Related]
31. A double-dose hepatitis B vaccination schedule in travelers presenting for late consultation.
Wong J; Payne M; Hollenberg S
J Travel Med; 2014; 21(4):260-5. PubMed ID: 24796543
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.
Girndt M; Plüer M; Dellanna F; Michelsen AK; Beige J; Toussaint K; Wehweck HJ; Koch M; Hafezi Rachti S; Faust J; Bosselmann HP; Witzke O; Janssen RS;
Hum Vaccin Immunother; 2022 Nov; 18(6):2136912. PubMed ID: 36269938
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of non-responsiveness to an indigenous recombinant hepatitis B vaccine: a study among South Indian health care workers in a tertiary hospital.
Thomas RJ; Fletcher GJ; Kirupakaran H; Chacko MP; Thenmozhi S; Eapen CE; Chandy G; Abraham P
Indian J Med Microbiol; 2015 Feb; 33 Suppl():32-6. PubMed ID: 25657153
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B surface antigenemia following recombinant Engerix B hepatitis B vaccine in an 81-year-old ESRD patient on hemodialysis.
Onuigbo MA; Nesbit A; Weisenbeck J; Hurlburt J
Ren Fail; 2010 May; 32(4):531-2. PubMed ID: 20446799
[TBL] [Abstract][Full Text] [Related]
35. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B
Elhanan E; Boaz M; Schwartz I; Schwartz D; Chernin G; Soetendorp H; Gal Oz A; Agbaria A; Weinstein T
Clin Exp Nephrol; 2018 Feb; 22(1):151-158. PubMed ID: 28456864
[TBL] [Abstract][Full Text] [Related]
36. Seroprotection after hepatitis B vaccination in chronic kidney disease patients with modified schedule and dosage.
Siddiqui S; Malik A; Shukla I; Rizvi M; Haque SF
J Infect Dev Ctries; 2010 Jun; 4(6):389-92. PubMed ID: 20601791
[TBL] [Abstract][Full Text] [Related]
37. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.
Keating GM; Noble S
Drugs; 2003; 63(10):1021-51. PubMed ID: 12699402
[TBL] [Abstract][Full Text] [Related]
38. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
[TBL] [Abstract][Full Text] [Related]
39. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
Shouval D; Roggendorf H; Roggendorf M
Med Microbiol Immunol; 2015 Feb; 204(1):57-68. PubMed ID: 25557605
[TBL] [Abstract][Full Text] [Related]
40. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease.
Lacson E; Teng M; Ong J; Vienneau L; Ofsthun N; Lazarus JM
Hemodial Int; 2005 Oct; 9(4):367-75. PubMed ID: 16219057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
